Please provide your email address to receive an email when new articles are posted on . Direct-to-consumer testing, combined with clinical follow-up, helped identify patients with undiagnosed alpha-1 ...
Emphysema is not hereditary. It usually results from smoking or exposure to other harmful lung irritants. However, a rare genetic condition called alpha-1 antitrypsin deficiency (AATD) passed down in ...
NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung disease associated with alpha-1 antitrypsin deficiency (AATD) NTLA-3001 ...
Alpha-1 antitrypsin deficiency, AATD, is an inherited disease affecting the lung, liver, and, rarely, skin. Alpha-1 antitrypsin, AAT, is a protease inhibitor of the proteolytic enzyme elastase.
Krystal Biotech reports positive clinical data for KB408 and KB407, demonstrating safety and efficacy in AATD and cystic fibrosis patients. Krystal Biotech, Inc. has announced promising clinical ...
OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results